Search Results

Researchers say detailed studies are needed to determine whether diabetes drugs themselves or patients’ underlying health explain the observed eye-event risk

Integrating pharmacology, personalized nutrition, and precision medicine to improve management of obesity and type 2 diabetes.

Findings suggest GLP-1s may have protective properties for bone health.

Semaglutide may slow aging-related changes by reducing inflammation and excess fat, helping lower the risk of age-related diseases.

GLP-1 drugs may help treat more than obesity, but research is still evolving.

Lower GLP-1 prices may ease Medicare costs, but savings still fall short.